The abortion pill battle over mifepristone has again moved from the courts into the campaign spotlight, with decisions that affect how patients can obtain the medication colliding with the politics of the 2026 midterm elections, the Associated Press reported May 5. The report described how a federal appeals court ruling limited mail access to mifepristone prescriptions, followed by a temporary Supreme Court restoration of broader access while the justices continue to weigh the dispute. The near-term uncertainty, advocates on both sides said, could translate into voter turnout efforts as the election year advances.
The appeals-court decision marked a significant shift in federal abortion policy, according to the Associated Press account, and it arrived after the Supreme Court’s 2022 ruling that allowed states to enforce abortion bans. After the appeals court’s Friday ruling restricting mail access, the Supreme Court on Monday restored broad access to the drug while it further considers the case. While the Associated Press said it was too early to determine whether the latest rulings would affect specific races, it cited both abortion-rights groups and abortion opponents preparing strategies aimed at mobilizing supporters.
Abortion rights strategists and pollsters framed the issue around access volatility, particularly for medication abortion obtained via telehealth. Celinda Lake, a Democratic pollster, said the ruling reminded voters that abortion medication access through telehealth is not guaranteed even in states where abortion rights are written into state law, the Associated Press reported. Lake also said the opportunity for Democrats is “tremendous” despite calling it “horrific,” arguing it can be used to tell voters what could be at stake in the midterm elections.
Mini Timmaraju, president and CEO of the abortion rights group Reproductive Freedom for All, told the Associated Press that her group would incorporate the volatility of abortion access into its strategy. Timmaraju said her outreach would include contacting voters who supported Donald Trump as well as voters who supported abortion rights in their state elections in 2024. She argued in the Associated Press report that “The only way for us to really stop this back and forth is to have abortion access be legal in all 50 states,” and she added that she viewed federal legislation as necessary to achieve that outcome.
Republicans, meanwhile, were portrayed by the Associated Press as facing internal strain as anti-abortion organizations pressed the administration for faster or stronger action. The report said the most urgent focus for anti-abortion groups includes an FDA safety review of mifepristone, which some groups hope will result in further restrictions. The Associated Press said that those restrictions could include blocking prescribing via telehealth platforms.
In the report, anti-abortion groups also escalated their messaging toward FDA leadership. On Monday, SBA Pro-Life America called for FDA commissioner Dr. Marty Makary’s firing, according to the Associated Press account, and the report included a response that the administration said it was “taking care to do this study properly and in the right way.” Marjorie Dannenfelser, SBA Pro-Life America’s president, said in a statement carried by the Associated Press that it was “a five-alarm crisis for the pro-life movement and for the GOP,” arguing that the GOP cannot win without enthusiasm driven by leadership from the top.
The Associated Press report also described how President Trump’s abortion approach has been mixed: it said he had taken steps that abortion opponents have cheered, including an effort to withhold funds from Planned Parenthood and investigations into states that require state-regulated health insurance plans to cover abortion. At the same time, the AP said Trump has sometimes tried to steer away from abortion as a federal issue, arguing the matter should be left to the states. It added that Trump publicly supported abortion rights until entering politics in 2015, and that Melania Trump announced broad support for abortion rights in 2024.
Marc Wheat, general counsel at former Vice President Mike Pence’s political advocacy group Advancing American Freedom, told the Associated Press that his group would increase pressure on the administration. Wheat said it would include urging the FDA to speedily release documents about mifepristone that it owes the group through a lawsuit. In the report, Wheat also asserted that Trump thinks “pro-life is a loser,” and he suggested Trump might see that pro-life voters “may not turn out in the numbers that he needs.”
The Associated Press report said Republicans and Democrats also remain constrained by public opinion that does not neatly map onto a single nationwide policy preference. It said about two-thirds of Americans opposed nationwide bans on mifepristone, citing a KFF poll conducted late last year. The report also cited AP-NORC polling that found about two-thirds of U.S. adults say abortion should be legal in all or most cases, while relatively few said abortion should be illegal in all cases.
For anti-abortion groups that have criticized incremental progress by allies, the Associated Press report pointed to a focus on partial victories. John Mize, CEO of Americans United for Life, told the outlet he was focused on incremental wins rather than seeking sweeping changes that some allies have advocated. He said in the report, “I think there is advancement being made in a positive direction,” and he added that while it may not match the pace some in the pro-life movement want, he viewed it as an “acceptable place of where we’re at culturally.”